The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer.
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Matthew T Campbell
Honoraria - Apricity Health; Apricity Health (Inst); Aravive (Inst); Astellas Pharma; AstraZeneca (Inst); Axdev; Eisai; EMD Serono; Exelixis; Exelixis (Inst); Genentech/Roche; Janssen Oncology (Inst); Medscape; Pfizer; Pfizer (Inst); Seagen
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Exelixis; Genentech; Pfizer
Research Funding - Apricity Health (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Pfizer; Roche
 
Rebecca Tidwell
Research Funding - Galera Therapeutics (Inst)
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech; IDEAYA Biosciences; Immunomedics; Janssen; Loxo; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen; Taiho Pharmaceutical
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Sangeeta Goswami
No Relationships to Disclose
 
Omar Alhalabi
Consulting or Advisory Role - Seagen
 
Ana Cecilia Adriazola
No Relationships to Disclose
 
Leah Shaw
No Relationships to Disclose
 
Yin Ye
No Relationships to Disclose
 
Jianfeng Chen
No Relationships to Disclose
 
Xinmiao Yan
No Relationships to Disclose
 
Linghua Wang
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca